Literature DB >> 22254201

Emerging concept of anti-hypertensive therapy based on ambulatory blood pressure profile in chronic kidney disease.

Kouichi Tamura1, Tomohiko Kanaoka, Masato Ohsawa, Sona Haku, Kengo Azushima, Akinobu Maeda, Toru Dejima, Hiromichi Wakui, Motoko Ozawa, Atsu-Ichiro Shigenaga, Yoshiyuki Toya, Satoshi Umemura.   

Abstract

Presently hypertensive patients with chronic kidney disease (CKD) particularly diabetic nephropathy are increasing in number, and cardiovascular and renal complications are the most common cause of death in these patients. The control of blood pressure (BP) is an important issue in cardiovascular and renal protection in hypertensive patients with CKD. Although hypertension is usually diagnosed based on measurements of BP recorded during a visit to a physician, that is, office BP, several studies have shown that target organ damage and prognosis are more closely associated with ambulatory BP than with office BP. It should be important to achieve the target absolute BP levels in hypertensive patients obtained either by office or home measurements or by ambulatory recordings for the cardiovascular and renal protection. Noninvasive techniques for measuring ambulatory BP have allowed BP to be monitored during both day and night. Additionally, ambulatory BP monitoring can provide information on circadian BP variation and short-term BP variability, which is suggested to be associated with cardiovascular and renal morbidity and mortality. This review will briefly summarize the emerging concept of anti-hypertensive therapy based on ambulatory BP profile in hypertensive patients with CKD.

Entities:  

Keywords:  Blood pressure variability; chronic kidney disease; diabetic nephropathy; hypertension; renin-angiotensin system

Year:  2011        PMID: 22254201      PMCID: PMC3253516     

Source DB:  PubMed          Journal:  Am J Cardiovasc Dis        ISSN: 2160-200X


  38 in total

1.  Identification of an increased short-term blood pressure variability on ambulatory blood pressure monitoring as a coronary risk factor in diabetic hypertensives.

Authors:  Motoko Ozawa; Kouichi Tamura; Yasuko Okano; Kouhei Matsushita; Mai Yanagi; Yuko Tsurumi-Ikeya; Jin Oshikawa; Tatsuo Hashimoto; Shinichiro Masuda; Hiromichi Wakui; Atsu-Ichiro Shigenaga; Kouichi Azuma; Tomoaki Ishigami; Yoshiyuki Toya; Toshiyuki Ishikawa; Satoshi Umemura
Journal:  Clin Exp Hypertens       Date:  2009-05       Impact factor: 1.749

2.  The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus.

Authors:  Emi Ushigome; Michiaki Fukui; Masahide Hamaguchi; Takafumi Senmaru; Kazumi Sakabe; Muhei Tanaka; Masahiro Yamazaki; Goji Hasegawa; Naoto Nakamura
Journal:  Hypertens Res       Date:  2011-08-04       Impact factor: 3.872

Review 3.  Neural cardiovascular regulation and 24-hour blood pressure and heart rate variability.

Authors:  G Parati; M Di Rienzo; G Mancia
Journal:  Ann N Y Acad Sci       Date:  1996-08-15       Impact factor: 5.691

4.  A possible relationship of nocturnal blood pressure variability with coronary artery disease in diabetic nephropathy.

Authors:  Kouichi Tamura; Yuko Tsurumi; Masashi Sakai; Yutaka Tanaka; Yasuko Okano; Junji Yamauchi; Tomoaki Ishigami; Minoru Kihara; Nobuhito Hirawa; Yoshiyuki Toya; Machiko Yabana; Yasuo Tokita; Toshimasa Ohnishi; Satoshi Umemura
Journal:  Clin Exp Hypertens       Date:  2007-01       Impact factor: 1.749

5.  Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.

Authors:  Yoshiyuki Morishita; Shiho Hanawa; Junko Chinda; Osamu Iimura; Sadao Tsunematsu; Eiji Kusano
Journal:  Hypertens Res       Date:  2010-12-02       Impact factor: 3.872

6.  Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.

Authors:  Hiroshi Kudo; Hisashi Kai; Hidemi Kajimoto; Mitsuhisa Koga; Narimasa Takayama; Takahiro Mori; Ayami Ikeda; Suguru Yasuoka; Takahiro Anegawa; Hiroharu Mifune; Seiya Kato; Yoshitaka Hirooka; Tsutomu Imaizumi
Journal:  Hypertension       Date:  2009-08-24       Impact factor: 10.190

7.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

8.  Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration: the Ohasama study.

Authors:  Yoriko Shintani; Masahiro Kikuya; Azusa Hara; Takayoshi Ohkubo; Hirohito Metoki; Kei Asayama; Ryusuke Inoue; Taku Obara; Yoko Aono; Takanao Hashimoto; Junichiro Hashimoto; Kazuhito Totsune; Haruhisa Hoshi; Hiroshi Satoh; Yutaka Imai
Journal:  J Hypertens       Date:  2007-08       Impact factor: 4.844

9.  Relationship between the circadian rhythms of blood pressure and sympathovagal balance in diabetic autonomic neuropathy.

Authors:  V Spallone; L Bernardi; L Ricordi; P Soldà; M R Maiello; A Calciati; S Gambardella; P Fratino; G Menzinger
Journal:  Diabetes       Date:  1993-12       Impact factor: 9.461

Review 10.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors:  Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal:  Lancet       Date:  2005-12-10       Impact factor: 79.321

View more
  8 in total

Review 1.  Chronotherapy for hypertension in patients with chronic kidney disease: a systematic review and meta-analysis in non-black patients.

Authors:  Caixia Wang; Xilian Qiu; Linsheng Lv; Jianhua Huang; Shaomin Li; Tanqi Lou; Xun Liu
Journal:  Int Urol Nephrol       Date:  2016-11-14       Impact factor: 2.370

Review 2.  Diurnal Regulation of Renal Electrolyte Excretion: The Role of Paracrine Factors.

Authors:  Dingguo Zhang; David M Pollock
Journal:  Annu Rev Physiol       Date:  2019-10-21       Impact factor: 19.318

3.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

4.  L/N-type calcium channel blocker cilnidipine added to renin-angiotensin inhibition improves ambulatory blood pressure profile and suppresses cardiac hypertrophy in hypertension with chronic kidney disease.

Authors:  Tomohiko Kanaoka; Kouichi Tamura; Hiromichi Wakui; Masato Ohsawa; Kengo Azushima; Kazushi Uneda; Ryu Kobayashi; Tetsuya Fujikawa; Yuko Tsurumi-Ikeya; Akinobu Maeda; Mai Yanagi; Yoshiyuki Toya; Satoshi Umemura
Journal:  Int J Mol Sci       Date:  2013-08-16       Impact factor: 5.923

5.  Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease.

Authors:  Masato Ohsawa; Kouichi Tamura; Tomohiko Kanaoka; Hiromichi Wakui; Akinobu Maeda; Toru Dejima; Kengo Azushima; Kazushi Uneda; Ryu Kobayashi; Yuko Tsurumi-Ikeya; Yoshiyuki Toya; Tetsuya Fujikawa; Satoshi Umemura
Journal:  Int J Mol Sci       Date:  2013-07-24       Impact factor: 5.923

6.  An interesting link between quality of sleep and a measure of blood pressure variability.

Authors:  Kouichi Tamura; Kotaro Uchida; Tomoaki Ishigami
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-12-29       Impact factor: 3.738

7.  Effect of valsartan with bedtime dosing on chronic kidney disease patients with nondipping blood pressure pattern.

Authors:  Cheng Wang; Jun Zhang; Xun Liu; Cui-Cui Li; Zeng Chun Ye; Hui Peng; Zhujiang Chen; Tanqi Lou
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-09       Impact factor: 3.738

8.  Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.

Authors:  Kengo Azushima; Kazushi Uneda; Kouichi Tamura; Hiromichi Wakui; Masato Ohsawa; Ryu Kobayashi; Toru Dejima; Tomohiko Kanaoka; Akinobu Maeda; Yoshiyuki Toya; Satoshi Umemura
Journal:  Biomed Res Int       Date:  2014-04-08       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.